Skip to main content
. 2014 Jul 8;15(4):54–66. doi: 10.1120/jacmp.v15i4.4645

Table 1.

Summary of prescription and VMAT QA results for all treatment sites. Multiple entries for Patient 10 represent three lesions treated using a single isocenter

Phantom Isocenter Dose (Gy)
Treatment Site Pat Dose Fx # of Arcs Total MU TPS IC
%diffIC
3DVH
%diff3DVH
Prostate 1
1.8Gy/fx×37
1 353.1 70.4 71.3 1.3 69.9
0.7
SBRT Prostate 2
3.2Gy/fx×20
1 644.4 73.5 73.9 0.5 73.8 0.4
SBRT Lung 3
12Gy/fx×5
1 2550.0 59.5 60.7 2.0 58.3
2.0
4
12Gy/fx×4
1 2177.9 52.0 53.0
1.9
52.4 0.8
5
12Gy/fx×4
2 1349.1 54.8 55.4 1.5 53.9
1.6
1349.9
Rib 6
2.5Gy/fx×16
1 391.0 30.6 30.5
0.3
30.6 0.1
SBRT Liver 7
20Gy/fx×3
1 4446.3 62.7 63.5 1.3 61.7
1.6
SRS Spine 8 18Gy/fxx1 2 1683.0 16.9 16.8 0.6 16.9 0.2
3665.3
SBRT Spine 9
7Gy/fx×5
2 901.3 37.6 37.3
0.8
37.5
0.3
1038.7
SRS Ischial 10
8Gy/fx×1
1 1251.3 8.1 8.1
0.5
7.7
4.9
SRS Femoral
8Gy/fx×1
1 609.4
SRS Symphysis
8Gy/fx×1
1 1461.0

%diffIC=(ICIPS)/TPS; %diff3DVH=(3DVHIPS)/TPS.